KAZIA THERAPEUTICS LTD - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K report covers the month of August 2026 for Kazia Therapeutics Limited, a foreign private issuer. The filing documents the submission of a Prospectus Supplement to the U.S. Securities and Exchange Commission on August 28, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a capital market transaction rather than operational financial results.
Material Changes
The primary material change disclosed is the reduction of the maximum aggregate offering price for American Depositary Shares (ADSs) under the Sales Agreement with Leerink Partners LLC. The limit was decreased from $100,000,000 to $80,000,000.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, operational outlook, specific risks, or contingencies. The document serves solely to update the terms of the existing Sales Agreement dated March 17, 2026, which is part of a registration statement on Form F-3.
Investor Verification Checklist
- Verify the updated maximum offering amount of $80,000,000 for ADSs under the Sales Agreement with Leerink Partners LLC.
- Confirm the filing date of the Prospectus Supplement as August 28, 2026.
- Review the underlying Form F-3 registration statement (File No. 333-294392) for full terms of the sales agreement.
- Note that no financial performance data is included in this specific filing.